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Enzyme-responsive polyion complex (PIC)
nanoparticles for the targeted delivery of
antimicrobial polymers†
Ignacio Insua,a Evangelos Liamas,b Zhenyu Zhang,b Anna F. A. Peacock,a
Anne Marie Krachlerc,d and Francisco Fernandez-Trillo*a,d
Here we present new enzyme-responsive polyion complex (PIC) nanoparticles prepared from antimicro-
bial poly(ethylene imine) and an anionic enzyme-responsive peptide targeting Pseudomonas aerugino-
sa’s elastase. The synthetic conditions used to prepare these nanomaterials allowed us to optimise
particle size and charge, and their stability under physiological conditions. We demonstrate that these
enzyme responsive PIC nanoparticles are selectively degraded in the presence of P. aeruginosa elastase
without being aﬀected by other endogenous elastases. This enzyme-responsive PIC particle can exert an elas-
tase-speciﬁc antimicrobial eﬀect against P. aeruginosa without aﬀecting non-pathogenic strains of these bac-
teria. These targeted enzyme-responsive PIC nanoparticles constitute a novel platform for the delivery of
antimicrobial peptides and polymers, and can be a powerful tool in the current race against antimicrobial
resistance.
Introduction
There is an increasing concern with the emergence of
microbial strains that can resist the action of current
antimicrobials.1–3 As evidenced over the last decades, the
limited pipeline of new antibiotics cannot cope with this
increasing number of resistant microbes,4–6 and new anti-
microbial strategies are needed that go beyond the development
of new drugs.7,8 One such strategy is the re-evaluation of drug
candidates, which have been discarded due to toxicity and side
eﬀects. This is the case for antimicrobial peptides,9–11 that are
amongst the few last-resort treatments against multidrug
resistant strains.12,13
Despite being powerful antimicrobial agents, the wide-
spread use of antimicrobial peptides in the clinic is limited by
their inactivation by serum proteases, toxicity to eukaryotic
cells and high production cost.9–11 The positively-charged
amphiphilic structure of antimicrobial peptides is responsible
for damaging bacterial membranes and cytosol components,
resulting in a fast and multi-target antimicrobial action with
broad spectra, but also in toxicity to the host.9–11 Polymeric
mimics of these peptides have been developed as an aﬀordable
alternative with increased protease stability and selectivity for
prokaryotic cells. However, the clinical application of these
polymer mimics is compromised by poor bioavailability,
limited diﬀusion in tissues, polyelectrolyte complexation with
negatively charged microbial peptidoglycans and extracellular
polymers, and insuﬃcient toxicological characterisation.14,15
Further strategies to improve the therapeutic profile of anti-
microbial peptides and mimics include masking of the
positive charge.16 However this often results in a reduced
antimicrobial activity as a consequence of slow or incomplete
cleavage of the masking group.
Less explored has been the use of controlled (and ideally
targeted) delivery when optimising antimicrobial therapeutic
profile.17,18 However, this is a very attractive alternative to
improve the medical profile of current antimicrobials: strat-
egies that can deliver antimicrobials at the site of infection can
minimise oﬀ-target eﬀects such as toxicity or the emergence of
reservoirs of microbial resistance genes in non-pathogenic
strains such as commensal bacteria.5
Towards this end, here we present a new targeted enzyme-
responsive nanoparticle that selectively delivers antimicrobial
polymers in the presence of Pseudomonas aeruginosa, whose
infections are very hard to treat.19 In our system, the toxicity of
cationic antimicrobial poly(ethylene imine) (PEI) was mini-
mised through polyelectrolyte complexation with an anionic
peptide, to form well-defined polyion complex (PIC) nano-
particles (Scheme 1). We demonstrate that our synthetic
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approach is highly modular, letting us tune particle size and
charge, and the stability of the PIC nanoparticles under
physiological conditions. By introducing a P. aeruginosa’s
elastase (LasB) cleavable sequence into our anionic peptide,
PIC nanoparticles could be degraded in the presence of this
P. aeruginosa’s virulence factor,20,21 and more importantly,
remained unchanged when treated with human leucocyte elas-
tase (HLE), a human elastase secreted at the site of infection.
Finally, we demonstrate that these enzyme-responsive PIC
nanoparticles have a targeted antimicrobial eﬀect against
P. aeruginosa and that this antimicrobial eﬀect is not observed




Enzymes (Pseudomonas aeruginosa Elastase (LasB): EC
3.4.24.26 and Human Leucocyte Elastase (HLE): EC 3.4.21.37)
were purchased from Merck Millipore. Branched poly(ethylene
imine) 25 kDa average molecular weight (B-PEI25), 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid (HEPES), Luria Bertani
(LB) broth (Miller) and Dulbecco’s modified eagle medium
(DMEM) were bought from Sigma-Aldrich®. Fluorescamine
and dimethylsulphoxide (DMSO) were purchased from Acros
Organics™. Ethylenediaminetetraacetic acid (EDTA) was pur-
chased from Alfa Aesar®. Nylon 0.45 µm syringe filters were
purchased from Camlab. P. aeruginosa strains were kindly
donated by Suzanne M. J. Fleiszig. We studied PAO1V as a
pathogenic strain and a deletion strain of lasA and lasB genes
of PAO1V was used as LasB-negative control (ΔlasAB).22 Live/
Dead® BacLight™ viability kit was purchased from Thermo
Fisher Scientific Inc.
Instrumentation
Dynamic light scattering (DLS) and ζ-potential measurements
were carried out in a Zetasizer Nano ZS (Malvern Instruments
Ltd) stabilised at 37 °C. DLS was read at 173° (backscattering)
for 60 seconds in triplicate and ζ-potentials were recorded 30
times at 140 V. A FLUOstar Omega (BMGLabtech Gmbh)
microplate reader was used to measure fluorescamine reac-
tions. Atomic force microscopy (AFM) measurements were
carried out in 5 mM HEPES buﬀer at pH 7.4 with intermittent
contact mode, using a NanoWizard® II (JPK Instruments Ltd)
fitted with SiNi cantilevers (BudgetSensors®) with a spring
constant of 0.27 N m−1. PIC particle size was measured from
AFM images with ImageJ software (version 1.48v). FACS was
performed on an Attune® Acoustic Focusing Cytometer
(Applied Biosystems™) measuring 10 000 events per sample.
BacLight™ fluorescent dyes were excited at 488 nm and emis-
sion was read at 515–545 and 640 nm for green and red
probes, respectively.
Enzymatic degradation – fluorescamine assay
Stock solutions of peptide (1 mM) or succinyl casein (0.5 mg
mL−1) were prepared in 2.5 mM Na2B4O7 buﬀer at pH 8.0 with
10 mM CaCl2 and 10% DMSO. 125 µL of these substrate solu-
tions were added to a 96-well black-walled microplate and
mixed with 125 µL of the same buﬀer without DMSO, contain-
ing 0.6 µg of enzyme (LasB or HLE). Solutions of enzymes and
substrates alone were prepared as blanks. Every sample was
prepared in triplicate. The microplate was incubated at 37 °C
for 4 hours under orbital shaking. After 4 hours, 50 µL of
0.1 M ethylenediaminetetraacetic acid (EDTA) in water at pH
8.0 were added to each well to quench all enzymatic activity.23
Then, each sample was mixed in a 1 : 1 volume with a 1 mM
solution of fluorescamine24 in methanol. The microplate was
incubated at 37 °C under orbital shaking for 30 minutes. After
this time, fluorescence was measured exciting at 355 nm and
reading the emission at 460 ± 10 nm.
Preparation of PIC nanoparticles
For nanoparticles prepared at a 1 : 0.3 N : COOH ratio (defined
as the ratio between amines in PEI and carboxylic acids in the
peptides), stock solutions of B-PEI25 (2.5 mM in amines) and
Ac-C-E-GLA-E-C-OH (P1SH) (0.25 mM) in 5 mM 4-(2-hydroxy-
ethyl)piperazine-1-ethanesulfonic acid (HEPES) buﬀer at
pH 7.4 were prepared. Then, both solutions were filtered and
mixed drop-wise under stirring. The reaction mixture was
stirred at room temperature for 24 hours open to air to allow
Scheme 1 Assembly and oxidative cross-linking of PIC nanoparticles from P1SH (Ac-C-E-GLA-E-C-OH) and antimicrobial branched PEI. Degra-
dation of PIC nanoparticles by LasB and subsequent PEI release.
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thiol oxidation with atmospheric oxygen. PIC nanoparticles
prepared at diﬀerent N : COOH ratios were obtained by chan-
ging the concentration of peptide stock solution and mixing
with 2.5 mM B-PEI25 following the same protocol (Table S2†).
After 24 hours, samples were analysed directly by DLS and
ζ-potential without prior filtration.
Enzymatic degradation of PIC nanoparticles
1 mL of PIC nanoparticles prepared at 1 : 0.3 N : COOH ratio
was incubated at 37 °C with 50 µL (5 µg) of LasB in 2.5 mM
Na2B4O7 buﬀer at pH 8.0. As controls, PIC nanoparticles were
incubated under the same conditions with HLE (5 µg) or
Na2B4O7 buﬀer to assess the enzymatic specificity and eﬀect of
salts in the buﬀer, respectively. Each sample was prepared in
triplicate from three diﬀerent batches of PIC nanoparticles.
DLS data was acquired over time (1–4 hours). The number of
amines was monitored after 4 hours of incubation as
described before (fluorescamine assay).
Antimicrobial activity of PIC nanoparticles
1 mL aliquots of P. aeruginosa PAO1V and ΔlasAB cultures in
LB broth (OD600 = 1.0) were centrifuged and resuspended in
1 mL of DMEM. These samples were incubated at 37 °C for
6 hours under orbital shaking to allow LasB production. After
this time, samples were centrifuged and half of the super-
natant replaced with the same volume of 5 mM HEPES buﬀer
at pH 7.4 (live control), PIC nanoparticles (prepared at a 1 : 0.3
N : COOH ratio as described above) and 1.25 mM B-PEI25 in
5 mM HEPES buﬀer at pH 7.4. A dead control was also prepared
by replacing all the supernatant after centrifugation with 70%
v/v aqueous 2-propanol. Samples were resuspended and incu-
bated at 37 °C under orbital shaking. Each sample was prepared
in triplicate. Every hour, 200 µL of each sample were taken and
the rest was kept shaking at 37 °C. These 200 µL aliquots were
incubated in the dark for 10 minutes with 1 µL of a 10-fold
diluted 1 : 1 mixture of BacLight™ probes in DMEM. Dead
control samples had to be centrifuged and resuspended in assay
buﬀer before staining with fluorescent dyes. Then, samples were
analysed by FACS setting gates for dead bacteria in green versus
red emission dot plots from the live and dead controls.
Results and discussion
Peptide synthesis and enzymatic degradation
Our goal was to develop a delivery method that did not require
chemical modification of the antimicrobial. PIC particles25 are
ideal for this purpose because the cationic antimicrobial pep-
tides or mimics thereof can be encapsulated within a particle
formed upon polyelectrolyte complexation with negatively
charged materials. This strategy of complexing oppositely
charged materials has been extensively used to deliver other
“precious” therapeutics, in particular nucleic acids.26
In our case, PIC nanoparticles would be prepared by the
combination of a tailor-made anionic peptide and the posi-
tively charged backbone of the antimicrobial (Scheme 1). In
addition, we wanted our system to be selectively degraded in
the presence of pathogenic bacteria, but not in their absence:
for example, in the presence of commensal bacteria or non-
pathogenic strains, unable to produce virulence factors. As
such, our system would be pathogen specific and enable a tar-
geted delivery of the antimicrobial. Here we chose
P. aeruginosa as a model pathogen: P. aeruginosa is an opportu-
nistic pathogen commonly associated with hospital-acquired
infections, often colonising wounds and immunocompro-
mised patients.19 Interestingly, amongst the virulence factors
that P. aeruginosa secretes to mediate infection, LasB,20,21 a
zinc-metalloprotease, constituted an excellent target to develop
our system. LasB has elastolytic activity and a preference to
cleave sites with small hydrophobic residues.27,28 Thus, we
designed our anionic peptides to contain a short LasB-cleavable
sequence (e.g. GLA,27 Scheme 1) flanked by two glutamic acids,
responsible for providing overall negative charge to our peptide.
We postulated that multivalency would be lost upon LasB
mediated cleavage of the peptide, resulting in degradation of
the particle and delivery of the antimicrobial (Scheme 1).
Two peptides were prepared at this stage: P1, containing
the Gly-Leu-Ala sequence27 and P2, containing a tetraalanine
site,28 both sequences having been reported to be cleaved by
LasB. The N-terminus of both peptides was capped as a
neutral acetamide to mask the cationic amine functionality.
All peptides were prepared by solid-phase synthesis in good to
excellent yields and high purity without any chromatographic
purification (see ESI: section 3, Fig. S1–S6† for experimental
details and characterisation).
A fluorogenic assay was then used to evaluate enzymatic
degradation of these peptides.24 Peptides were incubated with
LasB, treated with fluorescamine and the increase in emission
at 460 nm correlated with the amount of amines produced
upon enzymatic hydrolysis of the peptides. In each assay,
degradation of succinyl casein by the evaluated elastases was
monitored, to confirm that the enzymes had not lost their
activity upon storage.29 Additionally, the values obtained from
fluorescence measurements were normalised to that produced
by a model peptide (H2N-LA-E-OH (P3), Fig. S7†), which
should be produced upon enzymatic hydrolysis of P1.27 In our
hands, the GLA sequence in P1 was degraded to a higher
extent than the tetraalanine in P2, showing an increase in
amine content of 60% after four hours (Fig. 1). More impor-
tantly, when these peptides were incubated with HLE, a
human elastase secreted by the immune system during inflam-
mation, little to no degradation was observed for both pep-
tides. This demonstrated that both of these peptides were
excellent candidates to develop LasB-responsive nanoparticles,
which would only be degraded by LasB, even if endogenous
elastases were present in the media. All subsequent experi-
ments were performed with P1 because it is degraded to a
greater extent by LasB.
PEI as a model antimicrobial polymer against P. aeruginosa
Having established the peptide sequence to be employed in
the synthesis of our enzyme-responsive PIC nanoparticles, we
Paper Polymer Chemistry





















































































then turned our attention to the choice of antimicrobial. PEI
has been reported as an eﬃcient antimicrobial against both
Gram positive and Gram negative bacteria.30,31 Its antimicro-
bial activity can be tuned as a function of its degree of branch-
ing and molecular weight. Moreover, PEI has been extensively
applied as a starting material for the preparation of polyelec-
trolyte complexes.25 These features, and its commercial avail-
ability, made it an ideal candidate with which we could
optimise the preparation of our PIC nanoparticles.
However, the antimicrobial activity of PEI towards
P. aeruginosa had not been reported. Thus, five commercial
PEIs of various molecular weights and branching were evalu-
ated for their antimicrobial activity against P. aeruginosa. A
pathogenic P. aeruginosa strain (PAO1V) was cultured overnight
in the absence or presence of diﬀerent concentrations of PEI
and viability checked using a LIVE/DEAD® staining assay
(Fig. S8†). This assay reports on membrane integrity and thus
is especially suited to evaluate the activity of antimicrobial pep-
tides and mimics. As expected, activity depended on the
amount of PEI used. Aggregates could be visibly observed on
the sides of the cuvettes for the larger polymers at the highest
concentration tested (0.1 mg mL−1), compromising the
characterisation of the system. These aggregates may form as a
result of the clustering of bacteria by the cationic polymers,32,33
or these polymers being trapped by debris from dead bacteria.
Increasing the molecular weight resulted in an increase in the
percentage of dead cells. Moreover, the results at 0.01 mg mL−1
suggested that branching had a beneficial eﬀect on antimicro-
bial activity. Therefore, B-PEI25 was selected as the candidate
PEI to prepare our enzyme-responsive PIC nanoparticles.
PIC nanoparticle synthesis
Enzyme-responsive PIC nanoparticles were prepared by mixing
stock solutions of the peptide (in 5 mM HEPES buﬀer at
pH 7.4) with a 2.5 mM stock solution of B-PEI25 prepared in the
same buﬀer. Initial attempts to make PIC nanoparticles with
P1 did not result in the formation of stable aggregates. Thus,
we decided to introduce two cysteine residues in our peptides,
to allow for chemical oxidation during the nanoparticle for-
mation and cross-linking of the peptides. This strategy has
been employed in the synthesis of other PIC complexes, such
as nucleic acid polyplexes.34–36 PIC nanoparticles were success-
fully made with this modified peptide (P1SH), by mixing
peptide and B-PEI25 stock solutions and allowing the nano-
particles to oxidise overnight under stirring and open to air
(Scheme 1). The kinetics of thiol cross-linking was studied by
monitoring the decrease of accessible free thiols during nano-
particle formation using Ellman’s reagent.37 Complete
depletion of thiols was observed after nine hours for P1SH in
the presence of B-PEI25, whereas only 13% of initial thiols con-
tained in P1SH had oxidised after ten hours in its absence
(Fig. S9†). This result is in agreement with the literature,
where it is proposed that electrostatic complexation of polyions
increases the local concentration of thiols and thus increases
oxidation rates.38
Diﬀerent mixtures of B-PEI25 to P1SH (expressed as
N : COOH ratio) were evaluated to determine the optimal ratio
to prepare PIC nanoparticles (Fig. 2, Table S2†). Of all the
N : COOH ratios tested, only those between 1 : 0.8 and 1 : 0.3
formed stable PIC nanoparticles. This phenomenon could be
due to the lack of enough peptide below 1 : 0.3 to condense
B-PEI25 into particles, and the generation of neutral and
unstable coacervates at equimolar mixtures of positive and
negative charge, in agreement with the decrease in ζ-potential
observed with increasing peptide content (Fig. 2b). Interest-
ingly, we were not able to form PIC nanoparticles in the pres-
ence of an excess of COOH groups (i.e. peptide). We believe the
nucleation of these PIC nanoparticles is driven by complexation
of the anionic peptides onto the B-PEI25 backbone. Once the
positive charges on the surface of the growing nanoparticles are
Fig. 1 Relative amine content in samples of LasB responsive anionic
peptides evaluated in this work. Relative amine content was calculated
from ﬂuorescamine conjugates formed following incubation with
enzymes for 4 hours and normalised to the ﬂuorescence observed with
a model degradation peptide (P3, H2N-LA-E-OH) (Fig. S7†). Peptide
blanks (i.e. without enzyme) in black. n = 3.
Fig. 2 (a) Hydrodynamic diameter (DH) and (b) ζ-potential of P1SH PIC
nanoparticles prepared at diﬀerent N : COOH ratios. (c) AFM characteri-
sation of PIC nanoparticles prepared at a 1 : 0.3 N : COOH ratio. D =
127 ± 42 nm, n = 48.
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neutralised, complexation of further peptide is hindered and
thus prevents the formation of negatively charged particles.
A clear trend was found in particle size, with smaller
particles being formed with decreasing amounts of peptide
(Fig. 2a). AFM measurements were carried out to confirm the
size and shape of these nanomaterials. PIC nanoparticles
prepared at a 1 : 0.3 N : COOH ratio were selected for AFM analy-
sis due to their narrow size distribution in DLS characterisation.
AFM images showed the presence of spherical nanoparticles of
127 ± 42 nm in diameter (Fig. 2c), in agreement with the 111 ±
35 nm hydrodynamic diameter measured by DLS.
Physiological stability of PIC nanoparticles
PIC aggregates are disrupted in the presence of other electro-
lytes, which can shield and weaken the electrostatic forces
holding the aggregates together, and potentially lead to the
rupture of the particles.25 In this regard, the high contents of
salts in the body could compromise the eﬃcacy of PIC nano-
particles in biological settings. With this in mind, the stability
of PIC nanoparticles under physiological conditions was
assessed by diluting them into a final concentration of
154 mM NaCl and incubating them at 37 °C.39 The size of PIC
nanoparticles incubated under these conditions was moni-
tored by DLS over four hours (Fig. 3). All PIC nanoparticles
tested swelled under experimental conditions, as expected
from the addition of small Na+ and Cl− ions that can permeate
these soft nanoparticles and shield the interactions between
the polyions. A trend in the extent of this swelling was
observed and, in general, decreasing the amount of P1SH (i.e.
COOH component) resulted in nanoparticles with increasing
swelling. Interestingly, only the nanoparticles prepared at a
1 : 0.3 N : COOH ratio remained stable in size after the initial
swelling for the whole duration of the experiment, with all of
the other nanoparticles eventually reducing their size after two
hours of incubation. PIC nanoparticles prepared at high
N : COOH ratios were the most unstable and no aggregates
could be detected for most of these systems following incu-
bation for at least two hours (Fig. 3, hollow symbols).
DLS autocorrelation function curves (Fig. S10†), size distri-
butions (Fig. S11†) and count plots (Fig. S12†) strongly support
these observations: while PIC nanoparticles prepared with
higher concentrations of peptide (N : COOH ratios
1 : 0.8–1 : 0.6) were unable to scatter light following incubation
with NaCl, in some cases for as little as two hours, those prepared
with a lower proportion of peptide (N : COOH ratios 1 : 0.5–1 : 0.3)
did produce autocorrelation curves that could be fitted by the DLS
software. However, only those prepared at a 1 : 0.3 N : COOH ratio
were stable enough to scatter light over a prolonged period of
time, as observed in the detection counts. Consequently, PIC
nanoparticles prepared at this N : COOH ratio of 1 : 0.3 were
selected for biological studies due to their higher stability.
A similar eﬀect was observed when particles were incubated
with other biologically relevant cations, such as Ca2+
(Fig. S13†). Multivalent cations have a high aﬃnity for
polyanionic peptides and thus our PIC particles swelled when
exposed to CaCl2, as evidenced by the shift in their DLS
autocorrelation curves towards longer relaxation times. This
swelling was bigger with bigger amounts of CaCl2 added and
resulted in uneven light scattering profiles and multimodal
size distributions at the highest concentrations tested.
Enzymatic degradation of PIC nanoparticles
The enzyme-triggered disassembly of these (1 : 0.3)-PIC nano-
particles was evaluated first by DLS, monitoring the amount of
light scattered by three diﬀerent batches of these nanomaterials
when exposed to LasB at 37 °C (Fig. 4, hollow circles). Even after
only one hour of incubation, PIC nanoparticles treated with
LasB scattered 25% less light, and this scattering kept decreas-
ing for the duration of the experiment, reaching 40% of the
initial scattering intensity after four hours.
As a comparison, incubation with HLE caused nano-
particles to scatter 15% more light after one hour incubation
and remained close to 100% of the initial scattering for the
duration of the experiment (Fig. 4, hollow squares). This
initial increase in scattering intensity may be due to the swel-
ling of the PIC nanoparticles after addition of the enzyme
Fig. 3 Relative change in size for P1SH PIC nanoparticles prepared at
diﬀerent N : COOH ratios and incubated under simulated physiological
conditions (154 mM NaCl, pH 7.4, 37 °C). Particle size was normalised to
that of a control in the absence of NaCl (1×). n = 3.
Fig. 4 Normalised detection counts (%) for P1SH PIC nanoparticles pre-
pared at a 1 : 0.3 N : COOH ratio in the absence (●) and presence of LasB
(○) and HLE (□). Data normalised to the initial counts for each of the
individual experiments. n = 3.
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buﬀer (2.5 mM Na2B4O7, pH 8.0), in a similar fashion to the
swelling observed under physiological conditions (Fig. 3). A
similar swelling was observed when PIC nanoparticles were
incubated with this buﬀer in the absence of any of the
enzymes (Fig. 4, dark circles). No significant diﬀerence was
observed when this scattering was compared to that of HLE,
proving that the human enzyme was not having an eﬀect on
the stability of these PIC nanoparticles. A similar eﬀect could
be observed in the DLS size distributions (Fig. S14†) with
broader distributions and smaller sizes being observed upon
treatment with LasB, as opposed to the almost invariable
profile for HLE and the buﬀer controls.
The ability of LasB to degrade these PIC nanoparticles was
also assessed, as before, monitoring the formation of amines
upon enzymatic treatment. When PIC nanoparticles were
reacted with fluorescamine after four hours of incubation with
LasB or HLE, no significant diﬀerence in amine content was
observed for those treated with HLE when compared to PIC
nanoparticles incubated in the absence of any enzyme
(Fig. S15†). However, an increase in fluorescence emission (up
to 30%) was observed for the samples incubated with LasB.
This increase in the amount of amines, together with the DLS
data, confirms the selective cleavage of P1SH within the nano-
particle and consequent disassembly of these PIC nano-
particles when exposed to the bacterial elastase.
Antimicrobial activity of PIC nanoparticles
Having established the selectivity of the degradation of these
PIC nanoparticles in the presence of P. aeruginosa LasB, the
antimicrobial activity of these enzyme-responsive nano-
particles was assessed. P. aeruginosa PAO1V, a pathogenic
strain that secretes LasB, was incubated with PIC nanoparticles
(1 : 0.3 N : COOH ratio) or B-PEI25, aliquots were taken every
hour for four hours, and stained using the LIVE/DEAD® viabi-
lity kit. As expected, the antimicrobial activity for the PIC
nanoparticles was significantly reduced when compared to
B-PEI25, with the nanoparticles exhibiting, after two hour incu-
bation, less than 10% of the activity of B-PEI25 (Fig. 5), thus
confirming the potential of these PIC nanoparticles to reduce
the toxicity of antimicrobial polymers. This antimicrobial
activity was slowly recovered upon incubation with the bac-
teria, and up to 25% of the antimicrobial activity of B-PEI25
could be observed for PIC nanoparticles after four hours of
incubation, before the assay conditions become too harsh to
have viable controls of P. aeruginosa. When the same experi-
ment was performed with a LasB-deletion strain (ΔlasAB),
which does not produce this elastase, a similar reduction in
toxicity could be observed with the PIC nanoparticles (Fig. 5,
white bars), despite the slightly higher susceptibility of this
strain towards the antimicrobial polymer (Fig. S16 and S17†).
More importantly, the antimicrobial activity for the PIC nano-
particles against this ΔlasAB mutant remained constantly low
over the duration of the experiment, demonstrating that this
strain was unable to degrade the nanoparticle and thus release
the antimicrobial polymer.
Conclusions
Here, we have developed an easy methodology for the prepa-
ration, under aqueous conditions, of PIC nanoparticles from
an enzyme-responsive anionic peptide and a cationic anti-
microbial polymer. The size of these nanoparticles could be
tuned between 100 and 600 nm by simply adjusting the
N : COOH ratio. We have demonstrated that disulfide mediated
cross-linking and N : COOH ratios were fundamental to impart
these PIC nanoparticles with stability under physiological con-
ditions. Furthermore, we have shown that both the starting
peptide and the formed PIC nanoparticles can be selectively
degraded in the presence of LasB elastase, a virulence factor
secreted by the opportunistic pathogen P. aeruginosa, while no
degradation was observed in the presence of HLE, an elastase
secreted by human leucocytes. Finally, we demonstrate that
the toxicity of B-PEI25 was significantly reduced within these
nanoparticles. Antimicrobial activity was slowly recovered
when these PIC nanoparticles were incubated with a patho-
genic P. aeruginosa strain, while remaining non-toxic in the
presence of a strain that cannot produce the elastase.
We believe these enzyme-responsive PIC nanoparticles have
a great versatility and potential in the current fight against
antimicrobial resistance, and our eﬀorts to optimise antimicro-
bial activity, while maintaining the low toxicity against non-
targeted cells we observe here, will be reported in due course.
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Fig. 5 Normalised antimicrobial activity over time of P1SH PIC nano-
particles prepared at a 1 : 0.3 N : COOH ratio. Activity has been normal-
ised by dividing the relative antimicrobial activity (Fig. S17†) from PIC
nanoparticles by that of B-PEI25. *** p < 0.001 between PAO1V and
ΔlasAB (CI = 99.9%) after 4 hours. n = 3.
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